Dihydroartemisinin Loaded Nanostructured Lipid Carriers: Evaluation of Pharmacokinetics and Tissue Distribution After Intravenous Administration to Rats

    September 2010 in “ PubMed ”
    Xiaoyun Zhang, Hua Qiao, Jianping Liu, Haijun Dong, Chenlin Shen, Jingman Ni, Yanbin Shi, Ying Xu
    TLDR DHA-NLC may improve drug delivery and reduce side effects for cancer treatment.
    The study developed a rapid LC-MS/MS method to determine dihydroartemisinin (DHA) in rat plasma and tissues, comparing the pharmacokinetics and tissue distribution of DHA in nanostructured lipid carriers (DHA-NLC) versus a DHA solution. The DHA-NLC exhibited a longer mean residence time and higher AUC values in the liver, spleen, lung, brain, and muscle, but lower in the heart and kidney compared to the DHA solution. This indicated that DHA-NLC could be a promising sustained-release and drug-targeting system for antitumor drugs, potentially allowing for reduced dosage and decreased systemic toxicity.
    Discuss this study in the Community →